

- 236 – 238. DOI: 10. 1161/CIRCRESAHA. 113. 302813.
- [7] TANG J, LOBATO M E, HASSING L, et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation [J]. *Sci Adv*, 2015, 1 (3): pii: e1400223.
- [8] LINDAU A, HÄRDNER C, HERGETH S P, et al. Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression [J]. *Basic Res Cardiol*, 2016, 111 (2): 20. DOI: 10. 1007/s00395 – 016 – 0535 – 8.
- [9] SAYIN V I, KHAN O M, PEHLIVANOGLU L E, et al. Loss of one copy of Zfp148 reduces lesional macrophage proliferation and atherosclerosis in mice by activating p53 [J]. *Circ Res*, 2014, 115 (9): 781 – 789. DOI: 10. 1161/CIRCRESAHA. 115. 304992.
- [10] TANAKA S, MATSUMOTO T, MATSUBARA Y, et al. BubR1 Insufficiency Results in Decreased Macrophage Proliferation and Attenuated Atherogenesis in Apolipoprotein E – Deficient Mice [J]. *J Am Heart Assoc*, 2016, 5 (9). pii: e004081. DOI: 10. 1161/JAHA. 116. 004081.
- [11] OGURA M, AYAORI M, TERAOKA Y, et al. Proteasomal inhibition promotes ATP – binding cassette transporter A1 (ABCA1) and ABCG1 Expression and cholesterol efflux from macrophages in vitro and in vivo [J]. *Arterioscler Thromb Vasc Biol*, 2011, 31 (9): 1980 – 1987. DOI: 10. 1161/ATVBAHA. 111. 228478.
- [12] MÄKINEN P I, LAPPALAINEN J P, HEINONEN S E, et al. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors [J]. *Cardiovasc Res*, 2010, 88 (3): 530 – 538.
- [13] ZHAO J F, SHYUE S K, KOU Y R, et al. Transient Receptor Potential Ankyrin 1 Channel Involved in Atherosclerosis and Macrophage – Foam Cell Formation [J]. *Int J Biol Sci*, 2016, 12 (7): 812 – 823. DOI: 10. 7150/ijbs. 15229.
- [14] THORP E, CUI D, SCHRIJVERS D M, et al. MERTK receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoE – / – mice [J]. *Arterioscler Thromb*, 2008, 28 (8): 1421 – 1428. DOI: 10. 1161/ATVBAHA. 108. 167197.
- [15] HEO K S, CUSHMAN H J, AKAIKE M, et al. ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis [J]. *Circulation*, 2014, 130 (2): 180 – 191. DOI: 10. 1161/CIRCULATIONAHA. 113. 005991.
- [16] THORP E, VAISAR T, SUBRAMANIAN M, et al. Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase C δ , and p38 mitogen – activated protein kinase (MAPK) [J]. *J Biol Chem*, 2011, 286 (38): 33335 – 33344. DOI: 10. 1074/jbc. M111. 263020.
- [17] IVANOVA E A, OREKHOV A N. The Role of Endoplasmic Reticulum Stress and Unfolded Protein Response in Atherosclerosis [J]. *Int J Mol Sci*, 2016, 17 (2). pii: E193. doi: 10. 3390/ijms17020193.
- [18] LIU X, TANG Y, CUI Y, et al. Autophagy is associated with cell fate in the process of macrophage – derived foam cells formation and progress [J]. *J Biomed Sci*, 2016, 23 (1): 57. DOI: 10. 1186/s12929 – 016 – 0274 – z.
- [19] LIAO X, SLUIMER J C, WANG Y, et al. Macrophage autophagy plays a protective role in advanced atherosclerosis [J]. *Cell Metab*, 2012, 15 (4): 545 – 553. DOI: 10. 1016/j. cmet. 2012. 01. 022.
- [20] ZHAI C, CHENG J, MUJAHID H, et al. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque [J]. *Plos One*, 2014, 9 (3): e90563. DOI: 10. 1371/journal. pone. 0090563.
- [21] WANG B, ZHONG Y, HUANG D, et al. Macrophage autophagy regulated by miR-384 – 5p – mediated control of Beclin – 1 plays a role in the development of atherosclerosis [J]. *Am J Transl Res*, 2016, 8 (2): 606 – 614.
- [22] GARGIULO S, GAMBA P, TESTA G, et al. Relation between TLR4/NF- κ B signaling pathway activation by 27 – hydroxycholesterol and 4 – hydroxynonenal, and atherosclerotic plaque instability [J]. *Aging Cell*, 2015, 14 (4): 569 – 581. DOI: 10. 1111/ acel. 12322.
- [23] WAN J, SHAN Y, FAN Y, et al. NF- κ B inhibition attenuates LPS – induced TLR4 activation in monocyte cells [J]. *Mol Med Rep*, 2016, 14 (5): 4505 – 4510. DOI: 10. 3892/mmr. 2016. 5825.
- [24] WEI Y, NAZARI – JAHANTIGH M, NETH P, et al. MicroRNA-126, – 145, and – 155: a therapeutic triad in atherosclerosis? [J]. *Arterioscler Thromb Vasc Biol*, 2013, 33 (3): 449 – 454. DOI: 10. 1161/ATVBAHA. 112. 300279.
- [25] NAZARI – JAHANTIGH M, WEI Y, NOELS H, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages [J]. *J Clin Invest*, 2012, 122 (11): 4190 – 4202. DOI: 10. 1172/JCI61716.
- [26] HORIE T, BABA O, KUWABARA Y, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE – / – mice [J]. *J Am Heart Assoc*, 2012, 1 (6): e003376. DOI: 10. 1161/JAHA. 112. 003376.
- [27] WANG J, BAI X, SONG Q, et al. miR-223 Inhibits Lipid Deposition and Inflammation by Suppressing Toll – Like Receptor 4 Signaling in Macrophages [J]. *Int J Mol Sci*, 2015, 16 (10): 24965 – 24982. DOI: 10. 3390/ijms161024965.

(收稿日期: 2017 – 01 – 12; 修回日期: 2017 – 05 – 20)

(本文编辑: 鹿飞飞)